Los Angeles Capital Management
VERV

Los Angeles Capital Management’s Verve Therapeutics VERV Stock Holding History

Los Angeles Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-69,083
Closed -$776K – 1548
2025
Q2 		$776K Sell
69,083
-36,855
-35% -$210K ﹤0.01% 722
2025
Q1 		$484K Sell
105,938
-125,185
-54% -$839K ﹤0.01% 751
2024
Q4 		$1.3M Sell
231,123
-31,270
-12% -$176K 0.01% 547
2024
Q3 		$1.27M Buy
262,393
+19,925
+8% +$116K 0.01% 568
2024
Q2 		$1.18M Buy
+242,468
New +$1.52M ﹤0.01% 603
2022
Q2 		– Sell
-16,685
Closed -$381K – 1473
2022
Q1 		$381K Buy
+16,685
New +$477K ﹤0.01% 1144

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Los Angeles Capital Management's VERV Position: Q3 2025 in Review

Los Angeles Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 69,083 shares — an estimated $776K sold.

Los Angeles Capital Management first reported a position in VERV in Q1 2022 and held it in 6 quarters. The position peaked at $1.3M in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Los Angeles Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 69,083 Verve Therapeutics shares in Q3 2025, an estimated $776K.
  • Los Angeles Capital Management first reported a position in Verve Therapeutics in Q1 2022 and held it in 6 quarters.
  • Los Angeles Capital Management's Verve Therapeutics position peaked at $1.3M in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Los Angeles Capital Management's 13F filing for Q3 2025, filed 20 Oct 2025.